AbCellera to Present at Upcoming Investor Conferences in March
AbCellera (ABCL) executives to present at investor conferences, including 44th Annual TD Cowen Health Care Conference and KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
02/22/2024 - 08:15 PM
VANCOUVER, British Columbia --(BUSINESS WIRE)--
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following investor conferences:
44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time)
KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time)
Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website . Replays of each webcast will be available through the same links following the presentations.
About AbCellera Biologics Inc .
www.abcellera.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240221998933/en/
Inquiries
media@abcellera.com , +1(604)724-1242
bd@abcellera.com , +1(604)559-9005
ir@abcellera.com , +1(778)729-9116
Source: AbCellera Biologics Inc.
When will AbCellera executives present at the 44th Annual TD Cowen Health Care Conference?
AbCellera executives will present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024, at 11:50 a.m. Pacific Time (2:50 p.m. Eastern Time).
Which investor conference will AbCellera executives attend on March 20, 2024?
AbCellera executives will attend the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on Wednesday, March 20, 2024, at 8:15 a.m. Pacific Time (11:15 a.m. Eastern Time).
Where can the live audio webcasts of the presentations be accessed?
The live audio webcasts of the presentations can be accessed through links posted on AbCellera's Investor Relations website.
Will replays of the webcasts be available?
Yes, replays of each webcast will be available through the same links following the presentations.
ABCL Rankings
#5068 Ranked by Stock Gains
ABCL Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Country
CA
City
Vancouver
About ABCL
abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’
